Local chemotherapy implant to attack aggressive meningiomas
Official title: Local Delivery of Chemotherapy to Aggressive Meningiomas using a Bioresorbable Implant
Funded at Mayo Clinic Jacksonville · NIH-11379615 · Data updated 2026-11-12
A Mayo Clinic team is testing a bioresorbable implant that locally delivers chemotherapy to aggressive meningiomas to help prevent recurrence.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | June 23, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $620,671 |
| NIH project number | 1R01CA305145-01A1 |
| Project ID | NIH-11379615 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with aggressive meningiomas who are candidates for surgical intervention and adjuvant therapy.
✕Less likely to help
Patients with tumors not suitable for local implant delivery or those without surgical options may not benefit.
What this research studies
This project focuses on treating aggressive meningiomas by placing a dissolvable implant that releases chemotherapy directly at the tumor site, aiming to overcome limits of systemic drug toxicity. It builds on the idea that localized delivery can reach tumor cells left behind after surgery or those resistant to radiation. The study will evaluate how well the implant delivers the drug, how long it lasts in the brain, and potential safety concerns in adults. If successful, this approach could reduce tumor rebound and improve quality of life for patients who cannot be cured with surgery and radiotherapy alone.
Why it matters
Potential benefit: If successful, patients could experience longer control of their tumor with fewer systemic side effects and less chance of recurrence.
How similar studies have gone: Localized chemotherapy strategies exist for other brain tumors, but this approach for meningiomas is innovative and less proven.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Horbinski, Craig Michael — Mayo Clinic Jacksonville
- Study coordinator: Horbinski, Craig Michael
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.